Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung Cancer

Phase 2

• Conditions: Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung Cancer

• Registration Number: JPRN-UMIN000003698
• Lead Sponsor: Hyogo Cancer Center,Depatrment of Thoracic Oncology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-06-02
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

1)Pulmonary fibrosis detected by chest CT 2)History of drug induced interstitial pneumonia 3)History of severe drug allergy 4)History of active infection or other serious complication 5)History of poorly controlled pleural effusion, pericardial effusion, and ascites 6)Treated by flucytosine(5-FC) 7)History of continuous (watery) diarrhea 8)History of ileus 9)History of severe heart disease(uncontrollable arrhythmia, uncontrollable angina pectoris, heart failure, etc) 10)Uncontrollable hypertension 11)Uncontrollable diabetes mellitus 12)Current or previous history of hemoptysis or hemosputum 13)Current or previous (within the last 1 year) history of symptomatic cerebrovascular disease 14)Current or previous (within the last 1 year) history of GI perforation 15)Symptomatic brain metastasis 16)Traumatic fracture of unrecovery 17)The operation has been scheduled during the examination period 18)Tumor invasive to the chest Laege bleed vessel.Cavity inbrain or lung tumor 19)Evidence of bleeding diathesis or coagulopathy 20)Thorombosis that need to treat 21)History of active double cancer with in 5 years 22)History of active psychological disease 23)History of pregnancy or lactation 24)Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate

Secondary Outcome Measures

Name	Time	Method
Overall survival, Progression free survival , Disease control rate, Toxicity